Busulfan Plus Fludarabine Compared With Busulfan Plus Cyclophosphamide for AML Undergoing HLA-Haploidentical Hematopoietic Cell Transplantation: A Multicenter Randomized Phase III Trial.
Yiwen LingLi XuanNa XuFen HuangZhiping FanZiwen GuoXiaojun XuHui LiuRen LinSijian YuHaiyan ZhangHua JinMeiqing WuCan LiuXinquan LiangRuiming OuYuping ZhangXiaodan LiuHong QuXiao ZhaiJing SunYing ZhaoQi-Fa LiuPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
The BuFlu regimen has a lower TRM and RRT and similar relapse for patients with AML undergoing haplo-HCT compared with the BuCy regimen.
Keyphrases
- phase iii
- allogeneic hematopoietic stem cell transplantation
- double blind
- acute myeloid leukemia
- open label
- placebo controlled
- clinical trial
- phase ii
- stem cell transplantation
- bone marrow
- acute lymphoblastic leukemia
- high dose
- low dose
- study protocol
- cord blood
- cross sectional
- randomized controlled trial
- free survival
- cell death
- cell cycle arrest
- cell proliferation
- pi k akt